Triple Agonists (GLP-1/GIP/Glucagon) Class Overview Monograph

What Are Triple Agonists and How Do They Work?

Triple agonists are synthetic peptide molecules engineered to bind and activate three distinct G-protein-coupled receptors simultaneously: the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR). Each receptor arm contributes a distinct metabolic effect, and the three signals interact in ways that appear additive or synergistic on weight reduction and hepatic fat clearance. Retatrutide is the most clinically advanced molecule in this class.

GLP-1 Receptor Arm

GLP-1 receptor activation is the foundation shared with approved agents such as semaglutide and tirzepatide. GLP-1R agonism slows gastric emptying, suppresses appetite via hypothalamic and brainstem pathways, and augments glucose-dependent insulin secretion [1]. The appetite-suppression signal is particularly durable across GLP-1-based drug classes, making it the anchor of the triple agonist mechanism.

GIP Receptor Arm

GIPR co-agonism was first validated as weight-relevant in tirzepatide's clinical program. GIP potentiates insulin release at the pancreatic beta cell and, in adipose tissue, may increase lipid storage buffering capacity during caloric restriction, reducing free fatty acid spillover [2]. Central GIPR signaling in the hypothalamus also contributes to satiety signaling, though the exact weighting versus GLP-1R remains an area of active research.

Glucagon Receptor Arm

The GCGR component is what separates triple agonists from their dual-agonist predecessors. Glucagon receptor activation raises hepatic glucose output, increases resting energy expenditure through thermogenic mechanisms, and accelerates hepatic lipid oxidation [3]. In isolation, GCGR agonism would be hyperglycemic. Balanced against concurrent GLP-1R-mediated insulin secretion, the net glycemic effect is neutral to mildly beneficial, while the lipolytic and thermogenic effects remain intact. This balance is the core pharmacological engineering challenge of the class.

Retatrutide: The Prototype Triple Agonist

Retatrutide (LY3437943) is a once-weekly acylated peptide developed by Eli Lilly. It carries fatty acid chains for albumin binding, extending its half-life to approximately 6 days in humans and permitting weekly dosing. The molecule activates GLP-1R, GIPR, and GCGR with a receptor potency ratio designed to produce hepatic fat reduction without net hyperglycemia [4].

Phase 2 Obesity Trial (N=338)

The key phase 2 randomized controlled trial published in the New England Journal of Medicine enrolled 338 adults with obesity (BMI 30 to 50 kg/m²) and randomized them to once-weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, versus placebo over 48 weeks [5]. At 48 weeks, the 12 mg group achieved a mean body weight reduction of 24.2% compared with 2.1% for placebo (P<0.001). The 8 mg group reached 22.8% mean weight loss. Both figures exceed the 20.9% mean weight loss seen with semaglutide 2.4 mg at 68 weeks in STEP-1 (N=1,961) [6], and the 22.5% seen with tirzepatide 15 mg at 72 weeks in SURMOUNT-1 (N=2,539) [7]. Weight loss appeared to be dose-dependent and had not reached a clear plateau by week 48 in the highest-dose arms.

Phase 2 Type 2 Diabetes Trial

A separate phase 2 RCT (N=281) evaluated retatrutide in adults with type 2 diabetes over 36 weeks [8]. Retatrutide 12 mg reduced HbA1c by a mean of 2.02 percentage points from a baseline of approximately 8.3%, and produced 16.9% body weight reduction. Fasting glucose, triglycerides, and blood pressure all improved significantly versus placebo. The glucagon receptor component did not produce net hyperglycemia when balanced against GLP-1R-driven insulin augmentation, confirming the preclinical pharmacological hypothesis in humans.

Phase 3 Program

Eli Lilly has initiated the TRIUMPH phase 3 program for retatrutide. TRIUMPH-1 and TRIUMPH-2 are evaluating the 8 mg and 12 mg doses in adults with obesity with and without type 2 diabetes. TRIUMPH-3 targets MASLD/MASH. No phase 3 results have been published as of mid-2025; the program is expected to report primary endpoints in 2026.

Pharmacokinetics and Dosing Considerations

Absorption and Half-Life

Retatrutide is administered subcutaneously once weekly. Its acylation with a C20 fatty diacid enables reversible albumin binding, extending the effective half-life to approximately 6 days [4]. Steady-state plasma concentrations are reached by approximately week 4 to 6 of weekly dosing. Subcutaneous bioavailability is estimated at roughly 65% based on phase 1 data, comparable to semaglutide 2.4 mg (Wegovy).

Dose Escalation Schedule

Because GI tolerability limits rapid up-titration, the phase 2 obesity program used a structured titration: starting at 2 mg weekly for 4 weeks, advancing to 4 mg for 4 weeks, then stepping to the target maintenance dose (8 mg or 12 mg) [5]. Prescribers familiar with the tirzepatide escalation schedule (starting at 2.5 mg and titrating every 4 weeks) will recognize the same general design principle. Slower escalation reduces the incidence of treatment-emergent nausea and vomiting. The final FDA-approved escalation schedule, if the agent receives approval, may differ from phase 2 protocols.

Renal and Hepatic Adjustments

Phase 2 trials excluded patients with eGFR <30 mL/min/1.73 m² and those with severe hepatic impairment. Specific dose adjustment recommendations for moderate renal or hepatic impairment have not been formally published. Until phase 3 and full pharmacokinetic bridging studies report, prescribers should apply caution analogous to that used for semaglutide in patients with eGFR <15 or active hepatic disease.

Efficacy Across Metabolic Outcomes

Body Weight

The 24.2% mean weight loss at 48 weeks in the phase 2 obesity trial places retatrutide above any currently approved pharmacotherapy on a head-to-head numerical basis [5]. No direct randomized comparison with semaglutide 2.4 mg or tirzepatide 15 mg exists yet; indirect comparisons carry substantial methodological limitations.

Hepatic Steatosis and MASLD

The glucagon receptor arm drives hepatic lipid oxidation and reduces liver fat independent of caloric restriction alone [3]. In the phase 2 diabetes trial, hepatic fat fraction measured by MRI-PDFF decreased by a mean of 73% from baseline in the 12 mg group compared with 14% in the placebo group [8]. This degree of hepatic fat reduction is clinically relevant for MASLD and MASH, where a 30% relative reduction in liver fat correlates with histological improvement per the AASLD 2023 guidance on MASLD pharmacotherapy [9].

Cardiometabolic Markers

Retatrutide 12 mg reduced triglycerides by approximately 33%, LDL-C by roughly 8%, and systolic blood pressure by a mean of 6.5 mmHg in the phase 2 diabetes trial [8]. HDL-C increased by approximately 10%. These changes are consistent with the downstream effects of significant weight loss and are in the range observed with tirzepatide in SURPASS-2 (N=1,879) [10].

Glycemic Control

In patients with type 2 diabetes, the 2.02 percentage point HbA1c reduction at 36 weeks is among the largest reported for any single agent in this patient population [8]. The FDA's 2023 guidance on antidiabetic drug development considers a 0.3 percentage point difference versus active comparator as clinically meaningful; retatrutide's phase 2 reductions exceed currently approved GLP-1 receptor agonist benchmarks in magnitude.

Safety and Tolerability Profile

Gastrointestinal Adverse Effects

GI side effects are the dominant tolerability issue, consistent with all GLP-1-based therapies. In the phase 2 obesity trial, nausea occurred in 63% of subjects at the 12 mg dose versus 20% on placebo during the titration phase, but fell to below 15% at steady state [5]. Vomiting affected 28% during titration. Diarrhea and constipation each occurred in approximately 18 to 22% of the active groups. The GI profile is consistent in character with semaglutide and tirzepatide, though early titration-phase incidence rates appear numerically higher at the 12 mg target dose.

Nausea Management

The following prescriber framework for managing retatrutide-associated nausea is based on the dose-escalation designs used across GLP-1/GIP/GCGR phase 2 studies and analogous protocols from the tirzepatide prescribing information (PI). Clinicians should treat nausea prophylactically during each dose increase rather than reactively.

1. Extend the current dose level by 4 additional weeks if nausea at any step is grade 2 or higher (interfering with daily activity).
2. Add ondansetron 4 mg as needed before the weekly injection for the first 2 weeks of each dose step.
3. Advise patients to eat smaller meals, avoid high-fat foods within 2 hours of injection, and remain upright for 1 hour after eating.
4. Do not escalate to the next dose level until nausea at the current level has resolved to grade 0 or 1 for at least 2 consecutive weeks.

Cardiovascular Safety

No dedicated cardiovascular outcome trial (CVOT) for retatrutide has reported results. The FDA requires a CVOT for all antidiabetic agents per its 2008 guidance, and a GLP-1-class CVOT is standard for obesity agents following SELECT (semaglutide 2.4 mg, N=17,604) which showed a 20% reduction in MACE [11]. The TRIUMPH program has not publicly disclosed a dedicated CVOT design for retatrutide. Prescribers should assume cardiovascular benefit is not yet established for this agent.

Thyroid C-Cell Risk

All GLP-1R agonists carry an FDA-mandated boxed warning for thyroid C-cell tumors based on rodent carcinogenicity studies. This class warning extends to retatrutide by mechanism. The boxed warning is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) [12]. The added GCGR component does not independently create a new thyroid signal based on preclinical data available through mid-2025.

Pancreatitis

Acute pancreatitis risk with GLP-1-based therapies has been studied extensively. The LEADER trial (liraglutide, N=9,340) and SUSTAIN-6 (semaglutide, N=3,297) did not show a statistically significant increase in pancreatitis versus placebo [13,14]. Retatrutide phase 2 data reported one case of acute pancreatitis in the active arms; causality was not established. Prescribers should discontinue the agent if acute pancreatitis is confirmed.

Position in Therapy and Comparisons

Comparison With Approved Dual Agonist: Tirzepatide

Tirzepatide (Mounjaro for T2D, Zepbound for obesity) is a GLP-1R/GIPR dual agonist approved by the FDA in May 2022 and November 2023 respectively [15]. SURMOUNT-1 showed 22.5% mean weight loss at 72 weeks with tirzepatide 15 mg versus 2.5% placebo (P<0.001, N=2,539) [7]. Retatrutide's 24.2% at 48 weeks in a smaller phase 2 trial suggests a numerically greater weight loss signal, attributed in part to the added GCGR-mediated energy expenditure increase, but no head-to-head RCT exists. The shorter 48-week duration in the retatrutide trial makes comparison imprecise.

Comparison With GLP-1 Monotherapy: Semaglutide 2.4 mg

STEP-1 (semaglutide 2.4 mg, N=1,961) reported 14.9% mean weight loss at 68 weeks versus 2.4% placebo [6]. Retatrutide's phase 2 data at 48 weeks already exceeds this by roughly 9 percentage points in the 12 mg arm. For hepatic steatosis, the added glucagon receptor activity appears to provide a meaningful incremental benefit over GLP-1 monotherapy based on phase 2 liver fat data [8].

Who Is a Candidate?

Based on phase 2 inclusion criteria and the expected prescribing profile once approved, likely candidates include adults with BMI 30 kg/m² or greater, adults with BMI 27 kg/m² or greater with at least one weight-related comorbidity (per the obesity pharmacotherapy framework in the 2023 AHA/ACC/AAPA/ABC/ACPM/ADCES/AHNHA/AMA/ASH/ASPC/NHLBI/PCNA Guideline for Cardiovascular Risk Reduction) [16], and adults with biopsy-confirmed or imaging-confirmed MASLD or MASH where liver fat reduction is a treatment target.

Patients with a history of MTC, MEN2, active pancreatitis, or prior severe GI intolerance to GLP-1-based therapy are contraindicated or require careful risk-benefit analysis.

Other Agents in the Triple Agonist Pipeline

Retatrutide is the most advanced, but other molecules in this class are in active development.

Survodutide (BI 456906)

Survodutide is a GLP-1R/GCGR dual agonist from Boehringer Ingelheim, which does not include a GIPR component. Phase 2 data in MASLD/MASH showed a 48.6% rate of MRI-PDFF response (50% or greater liver fat reduction) at 24 weeks versus 14.9% placebo (P<0.001, N=187) [17]. Phase 3 is enrolling. Survodutide is frequently discussed alongside triple agonists because its glucagon receptor mechanism overlaps, but it lacks the GIP arm.

Pemvidutide (ALT-801)

Pemvidutide from Altimmune is a GLP-1R/GCGR dual agonist in phase 2. It differs from survodutide in fatty acid chain design and receptor bias. Phase 2 data (MOMENTUM trial, N=391) showed 15.6% mean weight loss at 48 weeks with preservation of lean mass at a proportion greater than that seen with semaglutide monotherapy [18]. Lean mass preservation is attributed partly to the GCGR arm's effect on gluconeogenesis and protein metabolism.

AMG 133 (Maridebart Cafraglutide)

AMG 133 from Amgen is a GLP-1R agonist/GIPR antagonist bispecific antibody. It blocks rather than activates GIPR, which is a different pharmacological strategy from retatrutide's GIPR co-agonism. Early phase 2 data showed 14.5% weight loss at 12 weeks with monthly dosing [19], though the longer-term data needed to compare with retatrutide are not yet available.

Prescribing Framework for Clinicians

Prescribers evaluating triple agonists for their patients should apply a structured decision process now, even before FDA approval, because patients may be approaching clinicians about these agents through clinical trials, off-label compound requests, or international pharmacy access.

Pre-Prescribing Checklist

• Confirm BMI threshold (30 kg/m² or greater, or 27 to 29.9 kg/m² with comorbidity per AHA/ACC 2023 guidance [16])
• Rule out personal or family history of MTC or MEN2
• Establish baseline HbA1c, fasting lipids, liver enzymes, renal function, and if MASLD is a target, baseline MRI-PDFF or FibroScan
• Review current diabetes medications: GLP-1 receptor agonists should not be combined; sulfonylureas and insulin may require dose reduction to prevent hypoglycemia when initiating a potent incretin-based agent
• Discuss realistic titration timelines: patients should understand that therapeutic weight loss at the target dose takes 12 to 20 weeks to become fully apparent

Monitoring During Therapy

Recheck HbA1c and fasting glucose at 8 and 16 weeks during titration if the patient has type 2 diabetes, as insulin or sulfonylurea doses may need downward adjustment. Monitor liver enzymes at 12 and 24 weeks if MASLD is present. Retatrutide-associated heart rate increases of 2 to 4 beats per minute were observed in phase 2, consistent with GLP-1-class effects; baseline and periodic pulse monitoring is appropriate [5].

MASLD and MASH: An Emerging Primary Indication

The AASLD 2023 practice guidance on MASLD states that no pharmacotherapy was approved for MASH at the time of publication, but endorsed the use of GLP-1-based agents as reasonable adjunctive therapy for weight reduction in MASLD given their indirect hepatic benefits [9]. Resmetirom (Rezdiffra) received FDA approval for MASH with fibrosis in March 2024, becoming the first approved MASH-specific therapy [20]. The triple agonist class, by adding direct GCGR-mediated hepatic fat oxidation to GLP-1-driven weight loss, may offer a more complete mechanism for MASLD/MASH than GLP-1 monotherapy or dual agonism alone. TRIUMPH-3 will test this hypothesis in a properly powered RCT.

The 73% relative reduction in MRI-PDFF at 48 weeks with retatrutide 12 mg in the phase 2 diabetes trial [8] is the largest hepatic fat reduction reported for any pharmacotherapy in a controlled setting to date, though the sample size was small and liver biopsy histology data in pure MASLD populations are pending.